Physician profile
Gemma Th Ko
NPI 1437167715
$1,607.36
in general payments reported to CMS, 2019-2025
13 companies · $336 in 2025
The $336 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $391 · 2020: $181 · 2021: $263 · 2022: $162 · 2023: $162 · 2024: $112 · 2025: $336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $610.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $610.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $356.43 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $344.52 | 2019-2025 | Repatha, Otezla |
| Sunovion Pharmaceuticals INC. | $221.55 | 2019 | |
| Lilly USA, LLC | $171.07 | 2020-2024 | Mounjaro, Zepbound |
| Otsuka America Pharmaceutical, INC. | $119.41 | 2024-2025 | Rexulti |
| Lundbeck LLC | $116.26 | 2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $94.26 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $67.17 | 2019-2024 | Farxiga |
| Lucid Diagnostics INC. | $33.39 | 2023 | |
| Janssen Pharmaceuticals, INC | $30.49 | 2019 | |
| Merck Sharp & Dohme LLC | $20.64 | 2021 | |
| Amarin Pharma, INC. | $17.78 | 2020 | |
| Pfizer INC. | $14.39 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gemma Ko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.